Abstract：【Objective】To explore the changes and clinical significance of serum five tumor markers and procalcitonin (PCT) levels before and after chemotherapy for lung adenocarcinoma.【Methods】A total of 124 patients with lung adenocarcinoma two were treated with paclitaxel (or docetaxel) chemotherapy on the basis of routine treatment.Five tumor cell markers in serum [carcinoembryonic antigen (CEA),alpha fetoprotein (AFP),glycoprotein antigen 19-9 (CA19-9),glycoprotein antigen 125 (CA-125),glycoprotein antigen 15-3 (CA15-3)] and PCT were detected. Changes of the above indicators before and after chemotherapy were compared between the chemotherapy effective group and the ineffective group,the two-year survival group and the death group.【Results】The overall analysis of patients with lung adenocarcinoma showed that the levels of serum CEA,CA-125 and PCT after treatment were lower than those before treatment (P<0.05).Among 124 patients with lung adenocarcinoma,74 patients (59.68%) were effective in treatment,and 50 patients (40.32%) were ineffective in chemotherapy.The serum CEA and CA-125 levels in the two groups after treatment were lower than those before treatment,and the serum PCT levels in the chemotherapy effective group after treatment were lower than those before treatment (P<0.05).After treatment,serum CEA,CA-125 and PCT levels in the effective group were lower than those in the ineffective group (P<0.05).Among 124 patients with lung adenocarcinoma,28 patients (22.58%) had a survival period of ≥ 2 years,and 96 patients (77.42%) died within 2 years.The levels of serum CEA,CA-125 and PCT in the two groups after treatment were lower than those before treatment,and those in the survival group were lower than in the death group (P<0.05).The rates of serum CEA,CA-125 and PCT level decrease in the survival group after chemotherapy were higher than those in the death group (P<0.05).【Conclusion】The changes of serum CEA,CA-125 and PCT levels are closely related to the curative effect and prognosis of patients with lung adenocarcinoma,which can be used to assist in evaluating the disease progression and prognosis of patients with lung adenocarcinoma.
徐李红, 王禺, 岳虹. 血清五项肿瘤标志物及降钙素原水平在肺腺癌化疗前后的变化及其临床意义[J]. 医学临床研究, 2022, 39(9): 1395-1398.
XU Li-hong, WANG Yu, YUE Hong. Level Changes and Clinical Significance of Serum Five Tumor Markers and Procalcitonin before and after Chemotherapy in Lung Adenocarcinoma. JOURNAL OF CLINICAL RESEARCH, 2022, 39(9): 1395-1398.
[1] DUBEY A K,GUPTA U,JAIN S.Epidemiology of lung cancer and approaches for its prediction:a systematic review and analysis[J].Chin J Cancer,2016,35(1):71. [2] 刘畅,赵晓珍,白月琴,等.肺腺癌患者临床参数与血清标志物的相关性分析[J].同济大学学报(医学版),2019,40(1):87-90. [3] TRAVIS W D,ASAMURA H,BANKIER A A,et al.The iaslc lung cancer staging project:proposals for coding t categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the tnm classification of lung cancer[J].J Thorac Oncol,2016,11(8):1204-1223. [4] 董芸,袁峥玺,姚原.肿瘤标志物SCC-Ag、Cyf21-1、CEA、ProGRP及NSE联合检测在肺癌诊断中的应用[J].中国实验诊断学,2019,23(3):384-386. [5] CASTELLANOS E,FEID E,HORN L.Driven by mutations:the predictive value of mutation subtype in EGFR-Mutated Non-Small cell lung cancer[J].J Thorac Oncol,2017,12(4):612-623. [6] 谭祥.血清肿瘤标志物CEA、CA724、CA242、CA19-9联合检测诊断肺癌的临床价值分析[J].标记免疫分析与临床,2017,24(8):900-904. [7] PEDERSEN J H,SAGHIR Z,WILLE M M,et al.Ground-glass opacity lung nodules in the era of lung cancer ct screening:radiology,pathology,and clinical management[J].Oncology (Williston Park),2016,30(3):266-274. [8] ALANNI R,HOU J,AZZAWI H,et al.Cancer adjuvant chemotherapy prediction model for non-small cell lung cancer[J].IET Syst Biol,2019,13(3):129-135. [9] POORE G D,KOPYLOVA E,ZHU Q,et al.Microbiome analyses of blood and tissues suggest cancer diagnostic approach[J].Nature,2020,579(7800):567-574. [10] 刘建斌,贾涛,展晖,等.血清PCT、sTREM-1对肺癌术后并发肺部细菌感染诊断及疗效评估的价值[J].实用癌症杂志,2017,32(8):1301-1304.
2022, Vol. 39 
